Edition:
United Kingdom

Endocyte Inc (ECYT.OQ)

ECYT.OQ on NASDAQ Stock Exchange Global Select Market

23.48USD
19 Oct 2018
Change (% chg)

$0.08 (+0.34%)
Prev Close
$23.40
Open
$23.36
Day's High
$23.49
Day's Low
$23.30
Volume
2,569,283
Avg. Vol
559,703
52-wk High
$23.54
52-wk Low
$2.86

Select another date:

Thu, Oct 18 2018

Deals of the day-Mergers and acquisitions

Oct 18 The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Thursday:

Novartis pushes deeper into nuclear medicine with $2.1 billion deal

ZURICH Novartis is paying $2.1 billion (£1.6 billion) for nuclear medicine specialist Endocyte in Chief Executive Vas Narasimhan's latest deal to reshape the Swiss drugs group from a pillmaker to a producer of sophisticated therapies.

Novartis pushes deeper into nuclear medicine with $2.1 billion deal

ZURICH Novartis is paying $2.1 billion for nuclear medicine specialist Endocyte in Chief Executive Vas Narasimhan's latest deal to reshape the Swiss drugs group from a pillmaker to a producer of sophisticated therapies.

UPDATE 2-Novartis pushes deeper into nuclear medicine with $2.1 bln deal

* Analysts say Q3 results take back seat to deal (Adds comments from CEO, shares, details throughout)

Novartis to buy cancer drugmaker Endocyte for $2.1 billion in cash

Novartis AG will acquire U.S.-based cancer drugmaker Endocyte Inc for $2.1 billion in cash as the Swiss drugmaker expands its radiopharmaceuticals business, the companies said on Thursday.

UPDATE 1-Novartis to buy cancer drugmaker Endocyte for $2.1 bln in cash

Oct 18 Novartis AG will acquire U.S.-based cancer drugmaker Endocyte Inc for $2.1 billion in cash as the Swiss drugmaker expands its radiopharmaceuticals business, the companies said on Thursday.

BRIEF-Novartis To Buy Endocyte In $2.1 Bln Deal

* NOVARTIS ANNOUNCES PLANNED ACQUISITION OF ENDOCYTE TO EXPAND EXPERTISE IN RADIOPHARMACEUTICALS AND BUILD ON COMMITMENT TO TRANSFORMATIONAL THERAPEUTIC PLATFORMS

Novartis to buy Endocyte for $2.1 billion in cash

Oct 18 Biopharmaceutical company Endocyte Inc said on Thursday that Novartis AG will acquire Endocyte in an all-cash deal for $24 per share, or a total equity value of about $2.1 billion.

BRIEF-Endocyte Enters Into Agreement to be Acquired by Novartis AG for $2.1 Billion

* ENDOCYTE ENTERS INTO AGREEMENT TO BE ACQUIRED BY NOVARTIS AG FOR $2.1 BILLION

BRIEF-Endocyte Reports Q1 Loss Per Share $0.16

* Q1 EARNINGS PER SHARE VIEW $-0.19 -- THOMSON REUTERS I/B/E/S

Select another date: